Testing Experimental Medication
common.study.values.description
“Renal PK Study of LC350189”
This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


Drug - LC350189 200 mg
Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LC350189 in Subjects With Varying Degrees of Renal Impairment
common.study.values.clinical-trial-id
NCT04066712
participant.views.study.view.id
aQWELd